Adam Schechter Net Worth

The estimated Net Worth of Adam H Schechter is at least $60.2 Milhão dollars as of 27 March 2024. Mr. Schechter owns over 72,435 units of Labcorp stock worth over $27,379,896 and over the last 15 years he sold LH stock worth over $27,939,072. In addition, he makes $4,902,600 as President, Chief Executive Officer, e Director at Labcorp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Schechter LH stock SEC Form 4 insiders trading

Adam has made over 38 trades of the Labcorp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 72,435 units of LH stock worth $15,811,836 on 27 March 2024.

The largest trade he's ever made was exercising 277,879 units of Labcorp stock on 1 November 2018 worth over $10,917,866. On average, Adam trades about 14,984 units every 59 days since 2010. As of 27 March 2024 he still owns at least 125,429 units of Labcorp stock.

You can see the complete history of Mr. Schechter stock trades at the bottom of the page.

Adam Schechter biography

Adam H. Schechter serves as President, Chief Executive Officer, Director of the Company. Adam H. Schechter has served as a director of the Company since April 1, 2013 and as the President and Chief Executive Officer of the Company since November 1, 2019. Prior to that, Mr. Schechter was an Executive Vice President of Merck & Co., Inc. from 2010 to 2018, where he was a member of Merck’s executive committee and pharmaceutical and vaccines operating committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. He previously served as President of Merck’s Global Human Health Division, which includes the company’s worldwide pharmaceutical and vaccine businesses from 2010 to 2018. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter’s extensive experience at Merck included global and U.S.-focused leadership roles spanning sales, marketing, and managed markets, as well as business and product development. He is a Board Member for Water.org and an executive board member for the National Alliance for Hispanic Health.

What is the salary of Adam Schechter?

As the President, Chief Executive Officer, e Director of Labcorp, the total compensation of Adam Schechter at Labcorp is $4,902,600. There are 1 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.

How old is Adam Schechter?

Adam Schechter is 55, he's been the President, Chief Executive Officer, e Director of Labcorp since 2019. There are 18 older and 7 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.

What's Adam Schechter's mailing address?

Adam's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.

Insiders trading at Labcorp

Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong, eDavid P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.

What does Labcorp do?

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.

Complete history of Mr. Schechter stock trades at DaVita Inc, Labcorp, eMerck & Co Inc

Labcorp executives and stock owners

Labcorp executives and other stock owners filed with the SEC include:

• Glenn Eisenberg,
  Chief Financial Officer, Executive Vice President
• Adam Schechter,
  President, Chief Executive Officer, Director
• Adam H. Schechter,
  Pres, CEO & Chairman
• Brian Caveney,
  Executive Vice President, President, Diagnostics and Chief Medical Officer
• Lance Berberian,
  Executive Vice President, Chief Technology Officer, Chief Information Officer
• Mark Schroeder,
  Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain
• Glenn A. Eisenberg,
  CFO & Exec. VP
• Mark S. Schroeder,
  Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain
• Dr. Paul R. Kirchgraber M.D.,
  Exec. VP & CEO of Covance Drug Devel.
• Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
  Exec. VP, Pres of Diagnostics & Chief Medical Officer
• Peter Neupert,
  Lead Independent Director
• Kerrii Anderson,
  Independent Director
• Garheng Kong,
  Independent Director
• Robert Williams,
  Independent Director
• Richelle Parham,
  Independent Director
• D. Gary Gilliland,
  Independent Director
• Jean-Luc Belingard,
  Independent Director
• Jeffrey Davis,
  Independent Director
• Clarissa Willett,
  Vice President, Investor Relations
• Peter Wilkinson,
  Senior Vice President, Chief Accounting Officer
• Paul Kirchgraber,
  Executive Vice President and Chief Executive Officer - Covance Drug Development
• Sandra Van Der Vaart,
  Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
• Amy Summy,
  Executive Vice President, Chief Marketing Officer
• Judith Seltz,
  Chief Human Resource Officer, Executive Vice President
• Chas Cook,
  VP of Investor Relations
• Dr. Marcia T. Eisenberg Ph.D.,
  Chief Scientific Officer & Sr. VP
• Lance V. Berberian,
  Exec. VP and Chief Information & Technology Officer
• Peter J. Wilkinson,
  Sr. VP & Chief Accounting Officer
• Dr. Michelle Abelson Ph.D.,
  Laboratory Director of Operations
• Anita Z Graham,
  EVP, CHRO
• R Sanders Williams,
  Director
• Edward T Dodson,
  Principal Accounting Officer
• Lisa J Uthgenannt,
  Chief Human Resources Officer
• David P King,
  Director
• M. Huff Gary,
  CEO, LabCorp Diagnostics
• John D Ratliff,
  CEO, Covance Drug Development
• F Samuel Iii Eberts,
  Chief Legal Officer, Secretary
• Robert E Jr Mittelstaedt,
  Director
• Kathryn E Wengel,
  Director
• Thomas Pike,
  Pres & CEO Clinical Business
• Arthur H Rubenstein,
  Director
• M Keith Weikel,
  Director
• William B Hayes,
  Sr. Vice President
• Wendy E Lane,
  Director
• Lidia Fonseca,
  Chief Information Officer
• Bradford T Smith,
  EVP, Chf Legal Offcr,Secretary
• Don M Hardison,
  EVP, COO
• Mahon Thomas P Mac,
  CEO and Chairman of the Board
• N Anthony Coles,
  Director
• William Haas,
  EVP, Sales & Marketing
• Andrew J Conrad,
  EVP, Chief Scientific Officer
• Goldman Myla Lai,
  EVP & Chief Medical Officer
• Benjamin R Miller,
  EVP, Oncology Products & Serv
• Andrew G Wallace,
  Director
• Allen W Troub,
  EVP, Western Operations
• Woodrow L Cook,
  EVP, Eastern Operations
• Richard L Novak,
  EVP & Strategic Planning
• Deborah L Keller,
  CEO, Covance Drug Development
• James T. Jr. Boyle,
  Senior Vice President
• Joseph L Herring,
  CEO of Covance Drug Division
• Mark E Brecher,
  Chief Medical Officer
• Kirsten Marie Kliphouse,
  Director
• Paul Rothman,
  Director
• Jonathan P. Di Vincenzo,
  EVP, Pres, Central Labs & Intl
• Megan D. Bailey,
  EVP, Chief Strategy Officer